These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16097841)

  • 1. Societal discounting of health effects in cost-effectiveness analyses: the influence of life expectancy.
    Polinder S; Meerding WJ; van Exel J; Brouwer W
    Pharmacoeconomics; 2005; 23(8):791-802. PubMed ID: 16097841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discounting future health gains: an empirical enquiry into the influence of growing life expectancy.
    Bobinac A; Brouwer W; van Exel J
    Health Econ; 2011 Jan; 20(1):111-9. PubMed ID: 20029933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discounting in decision making: the consistency argument revisited empirically.
    Brouwer WB; van Exel NJ
    Health Policy; 2004 Feb; 67(2):187-94. PubMed ID: 14720636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fair approach to discounting future effects: taking a societal perspective.
    Brouwer W; van Hout B; Rutten F
    J Health Serv Res Policy; 2000 Apr; 5(2):114-8. PubMed ID: 10947546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social time preferences for health and money elicited with a choice experiment.
    Meerding WJ; Bonsel GJ; Brouwer WB; Stuifbergen MC; Essink-Bot ML
    Value Health; 2010; 13(4):368-74. PubMed ID: 20070639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discounting in the economic evaluation of health care interventions.
    Krahn M; Gafni A
    Med Care; 1993 May; 31(5):403-18. PubMed ID: 8501989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counting and discounting gained life-years.
    Søgaard J; Gyrd-Hansen D
    Dev Health Econ Public Policy; 1998; 6():51-74. PubMed ID: 10662409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discount rate in the economic evaluation of prevention: a thought experiment.
    Bonneux L; Birnie E
    J Epidemiol Community Health; 2001 Feb; 55(2):123-5. PubMed ID: 11154251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discounting in cost-effectiveness analysis of healthcare programmes.
    Katz DA; Welch HG
    Pharmacoeconomics; 1993 Apr; 3(4):276-85. PubMed ID: 10146991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discounting health effects in pharmacoeconomic evaluations: current controversies.
    Bos JM; Postma MJ; Annemans L
    Pharmacoeconomics; 2005; 23(7):639-49. PubMed ID: 16173156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Unequal discounting of health care costs and effects causes confusion].
    van Ballegooijen M; de Kok IM; Habbema JD
    Ned Tijdschr Geneeskd; 2010; 154():A1970. PubMed ID: 20619050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a healthier discount procedure.
    Klock RM; Brouwer WB; Annemans LJ; Bos JM; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2005 Feb; 5(1):59-63. PubMed ID: 19807560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
    Westra TA; Parouty M; Brouwer WB; Beutels PH; Rogoza RM; Rozenbaum MH; Daemen T; Wilschut JC; Boersma C; Postma MJ
    Value Health; 2012 May; 15(3):562-7. PubMed ID: 22583467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.
    Cohen BJ
    Pharmacoeconomics; 2003; 21(2):75-87. PubMed ID: 12515570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.
    van Baal P; Meltzer D; Brouwer W
    Health Econ; 2016 Feb; 25(2):237-48. PubMed ID: 25533778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A low tension between individual and societal time aspects in health improved outcomes.
    Ortendahl M; Fries JF
    J Clin Epidemiol; 2006 Nov; 59(11):1222-7. PubMed ID: 17027434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theoretical arguments for the discounting of health consequences: where do we go from here?
    Lazaro A
    Pharmacoeconomics; 2002; 20(14):943-61. PubMed ID: 12403636
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.